Skip to main content
Spotlighting Zolbetuximab for Gastric/Gastroesophageal Junction Adenocarcinoma with Kohei Shitara, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Spotlighting Zolbetuximab for Gastric/Gastroesophageal Junction Adenocarcinoma: Kohei Shitara, MD In this interview from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Kohei Shitara, a Medical Oncologist at the National Cancer Center Hospital East in Japan, discusses his two abstracts investigating the efficacy of zolbetuximab in gastric cancers.  
Harnessing Precision Medicine in Oncology With Ofer Sharon, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Harnessing Precision Medicine in Oncology With Ofer Sharon, MD In this interview, Ofer Sharon, MD, the CEO of OncoHost, explains the unique opportunities for harnessing precision medicine in oncology, the unmet needs regarding biomarker development, and the potential of utilizing a multicomponent biomarker approa...
Thinking Outside the Box: Integrating Wellness and Natural Medicine Into Pharmacy With Swathi Varanasi, PharmD
Lyn Brook
Expert Analysis
Oncology Data Advisor® · Thinking Outside the Box: Integrating Wellness and Natural Medicine Into Pharmacy In this interview, Swathi Varanasi, PharmD, an integrative health pharmacist, shares her passion for incorporating wellness and natural medicine into pharmacy practice, including her pathway to studying integrative health, its speci...
Partnering With Patients: A Collection of Perspectives From ASCO 2023
Keira Smith
Expert Analysis
Oncology Data Advisor holds the utmost value for patient advocates and advocacy groups as they strive to prioritize patient-centered care and shared decision making throughout the cancer journey. At this year's American Society of Clinical Oncology (ASCO) Annual Meeting, Oncology Data Advisor spoke with numerous individuals representing diverse asp...
National Immunization Awareness Month With Richa Thakur, MD, and Waqas Haque, MD
Lyn Brook
Expert Analysis
This Oncology Data Advisor Fellows Forum interview celebrates National Immunization Awareness Month, featuring Richa Thakur, MD, Hematology/Oncology (Heme/Onc) Fellow at Northwell Health, and Waqas Haque, MD, Internal Medicine Resident at New York University, in a discussion about the importance of immunizations for cancer patients, their friends a...
Taking the Stage for Patient Advocacy With Megan-Claire Chase
Lyn Brook
Expert Analysis
Oncology Data Advisor® · Taking the Stage for Patient Advocacy With Megan-Claire Chase Megan-Claire Chase, a patient advocate and invasive lobular breast cancer survivor, recently appeared on the "Beyond Cancer" Episode of PBS's Stories from the Stage. In this interview, Ms. Chase shares more about the experience and the important messag...
Thinking Outside the Box: Integrating Wellness and Natural Medicine Into Pharmacy With Swathi Varanasi, PharmD
Keira Smith
Expert Analysis
In this interview, Swathi Varanasi, PharmD, an integrative health pharmacist, shares her passion for incorporating wellness and natural medicine into pharmacy practice, including her pathway to studying integrative health, its specific roles for helping patients with cancer achieve their goals, and ways that pharmacists and other health care profes...
Investigating Epcoritamab for Follicular Lymphoma and Beyond With Reid Merryman, MD
Keira Smith
Expert Analysis
Epcoritamab, a bispecific CD20-directed CD3 T-cell engager, is currently being investigated in numerous settings for patients with non-Hodgkin lymphomas. Recently, results were presented at the European Hematology Association (EHA) Congress for Cohorts 2A and 2B of the phase 1/2 EPCORE NHL-2 trial, which is investigating an epcoritamab combination for patients with relapsed/refractory follicular lymphoma. In this interview, Dr. Reid Merryman, an Attending Physician at Dana-Farber Cancer Center and one of the study's investigators, discusses the significance of these results and the efficacy of epcoritamab across the various tumor types being studied.  
Harnessing Precision Medicine in Oncology With Ofer Sharon, MD
Keira Smith
Expert Analysis
In this interview, Ofer Sharon, MD, the CEO of OncoHost, explains the unique opportunities for harnessing precision medicine in oncology, the unmet needs regarding biomarker development, and the potential of utilizing a multicomponent biomarker approach for understanding the mechanisms of therapy resistance and developing novel pathways for treatment.  
Groundbreaking Results of Mirvetuximab Soravtansine for Ovarian Cancer With Kathleen Moore, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Groundbreaking Results of Mirvetuximab Soravtansine for Ovarian Cancer With Kathleen Moore, MD Welcome to Oncology Data Advisor, a digital resource for the multidisciplinary cancer team. At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Kathleen Moore, MD, Associate Director of Clinical R...
Taking the Stage for Patient Advocacy With Megan-Claire Chase
Keira Smith
Expert Analysis
Megan-Claire Chase, a patient advocate and invasive lobular breast cancer survivor, recently appeared on the "Beyond Cancer" Episode of PBS's Stories from the Stage. In this interview, Ms. Chase shares more about the experience and the important messages for patients, survivors, and clinicians that she hoped to convey in her talk and throughout her advocacy.  
Studying Accelerated Brain Age and Neurocognitive Impairments in Childhood Cancer Survivors With Nicholas Phillips, MD, PhD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Accelerated Brain Age in Survivors of Childhood Cancer With Nicholas Phillips, MD In this interview from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Nicholas Phillips, a Physician Scientist at St. Jude Children's Research Hospital, discusses his research investigating accelerated brain age and associated neurocognitive impairments experienced by childhood cancer survivors.  
i3 Health Receives Joint Accreditation for Interprofessional Continuing Education™
Keira Smith
Press
i3 Health is honored to be awarded 4 years of Joint Accreditation for Interprofessional Continuing Education™ (IPCE) as a provider of continuing education for the interprofessional team by the governing bodies of the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the Amer...
Final Overall Survival Results of the CLEAR Study in Renal Cell Carcinoma With Thomas Hutson, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Final Overall Survival Results of the CLEAR Study in Renal Cell Carcinoma With Thomas Hutson, MD At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Thomas Hutson, Director of the Urologic Oncology Cancer Research and Treatment Center at Baylor Sammons Cancer Center, discusses the resul...
Reducing Drug Waste Through Dose Rounding of Bevacizumab With Puneeth Indurlal, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Reducing Drug Waste Through Dose Rounding of Bevacizumab With Puneeth Indurlal, MD In this interview from the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting, Dr. Puneeth Indurlal, Senior Director for Care Transformation at the US Oncology Network, discusses his team's abstract regarding dose rounding of bevacizumab, the potential for minimizing drug waste, and reducing the cost of care.  
Impacts of Social Determinants of Health on Triple-Negative Breast Cancer Treatment With Nicholas Robert, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Impact of Social Determinants of Health on TNBC Treatment With Nicholas Robert, MD In this interview from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Oncology Data Advisor speaks with Dr. Nicholas Robert, Chief Medical Officer for Ontada, about his team's abstract regarding the impacts of social determinants of health on genetic testing and treatment selection in triple-negative breast cancer (TNBC).  
Supporting Patients Through Employment Disruptions During Cancer With Michael Halpern, MD, PhD, MPH
Keira Smith
Expert Analysis
Oncology Data Advisor® · Supporting Patients Through Employment Disruptions During Cancer With Michael Halpern, MD In this interview from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Michael Halpern, Medical Officer in the National Cancer Institute's Healthcare Delivery Research Program, discusses his team's study investigating the effects of employment disruptions on financial hardship experienced by patients with cancer. Dr. Halpern shares advice for how employers can provide support and accommodation in the workplace for their employees during cancer treatment, as well as advice for clinicians on how to partner with patients to address financial hardships.  
Exploring the ARTISTRY-7 Trial of Nemvaleukin Alfa in Ovarian Cancer With Noelle Cloven, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Exploring the ARTISTRY-7 Trial of Nemvaleukin Alfa in Ovarian Cancer With Noelle Cloven, MD At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Noelle Cloven, a Gynecologic Oncologist at the Sarah Cannon Research Institute at Texas Oncology, sat down with Oncology Data Advisor to furthe...
Hematology/Oncology Trainee Experiences During the COVID-19 Pandemic and Beyond With Samuel Kareff, MD, MPH, and Ana Velazquez Mañana, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Hematology/Oncology Trainee Experiences During COVID-19: Samuel Kareff and Ana Velazquez Mañana This Oncology Data Advisor® Fellows Forum Interview features Dr. Samuel Kareff, Hematology/Oncology Chief Fellow at the University of Miami Sylvester Comprehensive Cancer Center, in discussion with Dr. Ana Velazquez Mañana, an Assistant Professor of Medicine in the Division of Hematology-Oncology at the University of California, San Francisco (UCSF), regarding the unique challenges faced by hematology/oncology trainees during the COVID-19 pandemic. Dr. Velazquez Mañana outlines the impacts on clinical training, research, and career development, as well as the positive changes that have been incorporated into the landscape for hematology/oncology trainees.  
Improving Outcomes for IDH1/2-Mutant Glioma in the INDIGO Study With Timothy Cloughesy, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Improving Outcomes for IDH1/2-Mutant Glioma in the INDIGO Study With Timothy Cloughesy, MD At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Timothy Cloughesy, Director of the Neuro-Oncology Program at the University of California Los Angeles (UCLA), sat down to further discuss his presen...